Friday, 16 October 2026European Markets

PARROT Stock Bullish Momentum With A 21.66% Rise Today

Loading stream...

(vianews) - the market ended the session with parrot (parro.pa) jumping 21.66% to €2.64 on wednesday while cac 40 rose 0.04% to €7,571.82.

parrot's last close was €2.17, 61.25% below its 52-week high of €5.60.

about parrot

parrot s.a. provides professional drones and software and services in france and internationally. the company also offers open flight, an open-source core of freeflight 7 app for anafi ai; air sdk, a development software kit for autonomous drones; ground sdk, a ground control station framework for mobile device; developer forum, an open-source development platform; and sphinx, a 3d photorealistic drone simulation tool. in addition, it offers c.a.d. modeling used for accessories 3d printing or additive manufacturing; olympe provides a python controller programming interface for anafi ai; and pdraw, an advanced video viewer for anafi ai media. the company offers its products for inspection, first responders, firefighters, search-and-rescue teams, security agencies, and surveying professionals. parrot s.a. was incorporated in 1994 and is headquartered in paris, france.

earnings per share

as for profitability, parrot has a trailing twelve months eps of €-0.91.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -37.52%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, parrot's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth grew by 3.3%, now sitting on 72.97m for the twelve trailing months.

volatility

parrot's last week, last month's, and last quarter's current intraday variation average was a negative 1.18%, a negative 0.60%, and a positive 3.11%.

parrot's highest amplitude of average volatility was 3.54% (last week), 2.03% (last month), and 3.11% (last quarter).

more news about parrot (parro.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com